A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Summary

The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)

Timeline

Start

2022-12-08

Primary completion

2023-10-10

Completion

2023-10-10

Outcome

Outcome not reported

Stopped (Enrollment): “N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility”

Drugs

Indications